ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) Ending Cash Position : €62.65 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Ending Cash Position?

ImmuneOnco Biopharmaceuticals (Shanghai)'s Ending Cash Position for the quarter that ended in Dec. 2024 was €62.65 Mil.

ImmuneOnco Biopharmaceuticals (Shanghai)'s quarterly Ending Cash Position declined from Dec. 2023 (€39.43 Mil) to Jun. 2024 (€31.61 Mil) but then increased from Jun. 2024 (€31.61 Mil) to Dec. 2024 (€62.65 Mil).

ImmuneOnco Biopharmaceuticals (Shanghai)'s annual Ending Cash Position declined from Dec. 2022 (€86.01 Mil) to Dec. 2023 (€39.43 Mil) but then increased from Dec. 2023 (€39.43 Mil) to Dec. 2024 (€62.65 Mil).

ImmuneOnco Biopharmaceuticals (Shanghai) Ending Cash Position Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Ending Cash Position Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

92.86

86.01

39.43

62.65

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Ending Cash Position	Get a 7-Day Free Trial			86.01	63.92	39.43	31.61	62.65

ImmuneOnco Biopharmaceuticals (Shanghai) Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	40.265	+	22.381
	=	62.65

ImmuneOnco Biopharmaceuticals (Shanghai)'s Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	32.376	+	30.27
	=	62.65

ImmuneOnco Biopharmaceuticals (Shanghai) Ending Cash Position Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (FRA:R9Z) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

01541:Hong Kong

Address

1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN

Website

http://cn.immuneonco.com

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

ImmuneOnco Biopharmaceuticals (Shanghai) Headlines

No Headlines